CellVoyant is an AI-first biotechnology company with a mission to create novel stem cell-based therapies for chronic diseases. Our technology uses AI-first live cell imaging to predict and optimise stem cell differentiation, to controllably manufacture any cell and tissue in the body at scale. CellVoyant is built on foundational work from the Carazo Salas lab at the University of Bristol.We’re working at the exciting intersection of cell biology, computer vision, engineering, and machine learning to industrialise next-generation science from research into the real world.Our mission is bold and ambitious and we have the best investors behind us from day 1. We’re backed by venture capital firms who were the earliest investors in AI pioneer DeepMind, the two leading AI-first drug discovery companies, Exscientia and Recursion, and self-driving challenger Wayve. We’re also supported by the founder/CEO of Abcam, which pioneered the antibody business.

CellVoyant

VIER is a company that offers AI-driven biotechnology solutions similar to CellVoyant.

VIER

4Dcell is a competitor to CellVoyant in the biotechnology sector, focusing on AI-driven solutions.

4Dcell

GlasPort Bio is a potential competitor to CellVoyant, offering biotechnology solutions.

GlasPort Bio

Reshape Biotech is a competitor to CellVoyant, offering biotechnology solutions.

Reshape Biotech

Adoptive Cell Therapy companies may be competitors to CellVoyant in the biotechnology and healthcare sectors.

Adoptive Cell Therapy

AI Drug Discovery Startups may be competitors to CellVoyant, utilizing artificial intelligence and machine learning for faster results in biotechnology.

AI Drug Discovery Startups

Cellvoyant is assumed to be a technology company with a focus on biotechnology and computational biology, potentially offering software and services for genomic data analysis, cellular imaging, and personalized medicine.

Cellvoyant

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Jun 22, 2024 6:46 PM	f6e18cd5
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Jun 22, 2024 9:18 PM	27057c4d
company summary	general
signals	general
crunchbase trigger	general	Nov 4, 2024 10:53 AM	e2f37188
crunchbase profile	general
li profile	general	Jun 22, 2024 6:46 PM	cfe2cdc6
translate crunchbase fundingrounds	general
peers	general
news basic	general	Jun 22, 2024 6:46 PM	3f94cf3c
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:CELLVOYANT

Cellvoyant